Respiratory Distress Syndrome in Newborns Pathophysiology, Contemporary Management, and Emerging Therapeutic Frontiers
1. Soni Akash
2. Khan Anas
3. Panwar Tapish
4. Sharma Charul
5. Muktarali kyzy Begimai
(1. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic
2. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic
3. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic
4. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic
5. Teacher, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.)
Abstract
Respiratory distress syndrome remains a leading cause of morbidity and mortality in preterm infants, arising from pulmonary surfactant deficiency and structural lung immaturity that compromise effective gas exchange at the critical transition to extrauterine life. This review examines the contemporary understanding of neonatal RDS, integrating recent advances in pathophysiological mechanisms, diagnostic methodologies, and evidence-based management strategies. A comprehensive literature search was conducted focusing on publications from 2017 to 2025, with particular emphasis on the European Consensus Guidelines 2025 update and emerging therapeutic modalities. The analysis reveals that antenatal corticosteroid administration, non-invasive respiratory support strategies, and minimally invasive surfactant administration have transformed outcomes, reducing mortality and bronchopulmonary dysplasia through lung-protective approaches. The 2025 European Consensus Guidelines recommend thin-catheter surfactant administration as the preferred route for spontaneously breathing preterm infants, conditional recommendations for nasal continuous positive airway pressure or synchronized nasal intermittent positive pressure ventilation as primary support modes, and emphasize the importance of avoiding mechanical ventilation when possible. Volume-targeted ventilation represents the optimal invasive strategy when required, with permissive hypercapbia and early caffeine administration facilitating weaning. Despite remarkable progress, significant challenges persist including optimal management of moderate and late preterm infants, prevention of bronchopulmonary dysplasia, and long-term neurodevelopmental sequelae. The integration of lung ultrasound for diagnosis and monitoring, refinement of surfactant administration techniques, and continued emphasis on non-invasive strategies offer promise for further improving outcomes in this vulnerable population.
Introduction
The first breath of a premature infant represents one of the most precarious moments in human life, as lungs that were never intended to function must suddenly sustain independent existence. For infants born before the completion of normal pulmonary development, this transition is fraught with peril. Respiratory distress syndrome, historically known as hyaline membrane disease, emerges from the convergence of surfactant deficiency and structural immaturity, creating a perfect storm of alveolar collapse, impaired gas exchange, and respiratory failure that has challenged neonatologists since the specialty's inception.
The journey of neonatal respiratory care reflects one of medicine's most remarkable narratives of progress. In the mid-twentieth century, the diagnosis of RDS in a premature infant carried a prognosis of near-certain death, with mortality rates exceeding 80% for the most immature infants. The introduction of mechanical ventilation offered hope but brought with it a new spectrum of complications including barotrauma, oxygen toxicity, and the chronic lung disease that came to be known as bronchopulmonary dysplasia. The landmark discovery of surfactant deficiency as the fundamental pathophysiological defect by Avery and Mead in 1959 laid the foundation for the development of exogenous surfactant therapy, which would eventually transform the natural history of this condition.
The contemporary era of neonatal respiratory care has been characterized by a philosophical shift from invasive to non-invasive approaches, from standardized to individualized ventilation strategies, and from survival as the sole outcome to optimization of long-term pulmonary and neurodevelopmental health. The European Consensus Guidelines, now in their seventh iteration as of 2025, reflect this evolution through increasingly sophisticated recommendations that integrate the latest evidence while acknowledging the complexities of applying rigid protocols to the heterogeneous population of preterm infants.
The pathophysiology of RDS, while conceptually straightforward—surfactant deficiency leading to alveolar collapse—encompasses a complex interplay of developmental immaturity, genetic predisposition, and environmental factors that influence disease severity and treatment response. The premature lung, with its thickened alveolar-capillary membrane, reduced surface area, and deficient antioxidant defenses, faces challenges that extend beyond simple surfactant replacement. The recognition that mechanical ventilation itself can injure the developing lung has driven the development of lung-protective strategies that seek to support gas exchange while minimizing secondary injury.
This review aims to provide a comprehensive examination of respiratory distress syndrome in newborns, encompassing the underlying pathophysiological mechanisms, epidemiological patterns, clinical manifestations, diagnostic approaches, and contemporary management strategies. Particular attention is directed toward the 2025 European Consensus Guidelines and emerging therapeutic modalities including minimally invasive surfactant administration, lung ultrasound, and novel ventilation strategies. Through this synthesis, we seek to illuminate both the remarkable progress achieved and the persistent challenges that demand continued innovation in the care of these vulnerable infants.
Methods
A comprehensive literature search was conducted to identify relevant publications addressing respiratory distress syndrome in newborn infants. The search encompassed databases including PubMed, MEDLINE, and the Cochrane Library, with primary focus on literature published between January 2017 and October 2025 to ensure inclusion of contemporary guidelines and emerging evidence. Search terms incorporated "respiratory distress syndrome," "neonatal," "preterm infant," "surfactant therapy," "non-invasive ventilation," "continuous positive airway pressure," "bronchopulmonary dysplasia," "lung ultrasound," "minimally invasive surfactant," and "antenatal corticosteroids."
Inclusion criteria prioritized original research articles, systematic reviews, meta-analyses, clinical practice guidelines, and randomized controlled trials specifically addressing neonatal respiratory distress syndrome or containing substantial neonatal subgroups. The methodological framework emphasized evidence-based guidelines including the European Consensus Guidelines on the Management of Respiratory Distress Syndrome 2025 update, the American Academy of Pediatrics recommendations, and the Cochrane systematic reviews on respiratory support strategies. Particular attention was directed toward studies comparing non-invasive ventilation modalities, evaluating surfactant administration techniques, and examining long-term pulmonary and neurodevelopmental outcomes.
The analysis synthesized data from multiple study designs, acknowledging the inherent challenges of neonatal research including ethical constraints on randomized trials, the difficulty of blinding interventions involving visible equipment, and the variability in definitions of respiratory distress syndrome and bronchopulmonary dysplasia across studies. Where evidence was limited or conflicting, findings were interpreted with appropriate caveats regarding the certainty of conclusions.
Results
Pathophysiology
The fundamental defect in respiratory distress syndrome is insufficient pulmonary surfactant, a complex mixture of phospholipids and proteins synthesized by type II pneumocytes that reduces surface tension at the air-liquid interface of the alveolus. Surfactant deficiency, resulting from premature birth before adequate surfactant production has been established, leads to increased surface tension, alveolar instability, and collapse at end-expiration. The resulting atelectasis decreases functional residual capacity, impairs gas exchange, and increases the work of breathing as the infant must generate higher transpulmonary pressures to reopen collapsed alveoli with each breath.
The premature lung faces additional challenges beyond surfactant deficiency. The alveolar-capillary membrane is thickened, reducing the efficiency of gas diffusion. The pulmonary capillary bed is underdeveloped, limiting perfusion and contributing to ventilation-perfusion mismatch. The chest wall of the preterm infant is highly compliant, offering little resistance to the recoil of the lung, which tends toward collapse. The respiratory muscles are weak and fatigue easily, compounding the increased work of breathing imposed by reduced lung compliance. The antioxidant defenses are immature, rendering the lung vulnerable to oxidative injury from oxygen therapy and inflammation.
The clinical consequences of these abnormalities include hypoxemia from ventilation-perfusion mismatch and shunt, hypercapnia from alveolar hypoventilation, and respiratory acidosis from carbon dioxide retention. The combination of hypoxemia and acidosis can precipitate pulmonary vasoconstriction, leading to persistent pulmonary hypertension of the newborn, which further exacerbates hypoxemia through right-to-left shunting. The metabolic demands of increased respiratory work can outstrip the infant's limited reserves, leading to exhaustion and respiratory failure if support is not provided.
The pathophysiology of RDS has important implications for therapy. Exogenous surfactant addresses the fundamental deficiency, rapidly improving lung compliance and gas exchange. Continuous positive airway pressure prevents alveolar collapse at end-expiration, maintaining functional residual capacity and reducing the work of breathing. Mechanical ventilation, when necessary, must be delivered in a manner that minimizes secondary lung injury from excessive pressure or volume. The recognition that lung injury can result from both inadequate support and excessive intervention has driven the development of lung-protective strategies that seek to optimize the balance between these competing risks.
Epidemiology and Risk Factors
Respiratory distress syndrome predominantly affects preterm infants, with incidence inversely proportional to gestational age. Approximately 80% of infants born at 26 to 28 weeks' gestation develop RDS, compared to approximately 50% of those born at 30 to 32 weeks and less than 5% of those born at 34 weeks or later. Despite this gradient, the majority of cases occur in late preterm and term infants simply because these births numerically predominate. The global burden of RDS is substantial, with an estimated 15 million preterm births annually worldwide and respiratory complications representing a leading cause of neonatal mortality.
Multiple risk factors for RDS have been identified beyond prematurity itself. Male sex confers increased risk, with male infants demonstrating higher incidence and severity of disease, possibly reflecting differences in lung maturation rates or surfactant production. Maternal diabetes mellitus, both pregestational and gestational, increases RDS risk through mechanisms involving delayed surfactant production and impaired lung fluid clearance. Perinatal asphyxia, cesarean delivery without labor, and multiple gestation are additional risk factors. Genetic polymorphisms in surfactant protein genes and other genetic variants influencing lung development may modify disease risk and severity.
Protective factors include antenatal corticosteroid administration, female sex, and certain genetic variants. Antenatal corticosteroids, typically betamethasone or dexamethasone, accelerate fetal lung maturation and surfactant production, reducing RDS incidence and severity when administered to mothers at risk of preterm delivery. The optimal timing of administration is between 24 hours and 7 days before delivery, though benefit is observed even with shorter intervals. Repeat courses may be considered for threatened preterm birth before 32 weeks if the initial course was administered at least one to two weeks earlier, though the potential benefits must be weighed against possible effects on fetal growth and neurodevelopment.
Clinical Manifestations
The clinical presentation of respiratory distress syndrome typically manifests within minutes to hours of birth, though onset may be delayed in infants receiving antenatal corticosteroids or those with milder disease. The characteristic findings include tachypnea with respiratory rates exceeding 60 breaths per minute, nasal flaring, intercostal and subcostal retractions, and expiratory grunting. Grunting, caused by partial closure of the glottis during expiration to generate positive end-expiratory pressure and prevent alveolar collapse, is a particularly characteristic finding of RDS. Cyanosis may be present and typically responds to supplemental oxygen, though severe disease may require higher oxygen concentrations or mechanical ventilation.
Auscultation reveals decreased breath sounds bilaterally, reflecting poor air entry from widespread atelectasis. Rales may be present but are not prominent. The infant's general appearance reflects the increased work of breathing, with use of accessory muscles, paradoxical chest wall movement, and signs of fatigue in severe cases. The severity of respiratory distress typically worsens over the first 24 to 48 hours, reaching a nadir before gradually improving as endogenous surfactant production increases and lung maturation proceeds.
The natural history of untreated RDS is progression to respiratory failure and death. With appropriate support, most infants survive the acute phase, though complications including air leak syndromes, intraventricular hemorrhage, patent ductus arteriosus, and bronchopulmonary dysplasia may develop. The severity of initial disease correlates with the risk of subsequent complications, particularly bronchopulmonary dysplasia, which develops in a substantial proportion of very preterm infants with severe RDS.
Diagnosis
The diagnosis of respiratory distress syndrome is primarily clinical, based on the characteristic presentation of respiratory distress in a preterm infant with consistent radiographic findings. The differential diagnosis includes transient tachypnea of the newborn, congenital pneumonia, sepsis, meconium aspiration syndrome, congenital heart disease, and primary pulmonary hypertension, among other conditions. The distinction from transient tachypnea of the newborn is particularly important in late preterm and term infants, as the management differs substantially.
Chest radiography remains the standard imaging modality for confirming the diagnosis. The characteristic findings of RDS include a diffuse reticulogranular or "ground glass" appearance, representing widespread alveolar atelectasis, with air bronchograms visible as dark branching structures against the opacified lung fields. The lung volumes are typically low, and the diaphragms may be obscured by the diffuse opacification. These findings reflect the underlying pathophysiology of surfactant deficiency and alveolar collapse.
Lung ultrasound has emerged as a valuable diagnostic tool for RDS, offering several advantages over chest radiography including the absence of ionizing radiation, bedside availability, and the ability to perform serial examinations. The characteristic lung ultrasound findings in RDS include B-lines (vertical artifacts arising from the pleural line), pleural line abnormalities, and lung consolidation with air bronchograms in severe cases. Studies have demonstrated that lung ultrasound can accurately differentiate RDS from transient tachypnea of the newborn, pneumonia, and other causes of respiratory distress, with sensitivity and specificity exceeding 90% in experienced hands. The technique is particularly valuable for guiding surfactant administration decisions and monitoring treatment response.
Arterial blood gas analysis provides important information regarding oxygenation, ventilation, and acid-base status. Typical findings in RDS include hypoxemia, hypercapnia, and respiratory acidosis, with the severity correlating with disease severity. Pulse oximetry provides continuous monitoring of oxygen saturation, with target ranges typically set at 90-94% for preterm infants to balance the risks of hypoxemia and hyperoxia. Capillary blood gas sampling offers a less invasive alternative for monitoring pH and carbon dioxide levels, though with less accuracy than arterial sampling.
Management
The management of respiratory distress syndrome has evolved considerably, with contemporary approaches emphasizing non-invasive strategies, lung-protective ventilation, and individualized care. The 2025 European Consensus Guidelines provide a comprehensive framework for management, integrating the latest evidence with expert consensus.
Prenatal Interventions
The prevention of RDS begins before birth with the identification of women at risk of preterm delivery and the administration of antenatal corticosteroids. A single course of prenatal corticosteroids is recommended for all women at high risk of preterm delivery from when pregnancy is considered potentially viable up to 34 completed weeks' gestation, ideally administered at least 24 hours before birth. Magnesium sulfate for fetal neuroprotection should be administered to women with imminent delivery before 32 weeks. Short-term tocolysis may be considered to allow completion of antenatal corticosteroids and transfer to a perinatal center.
Delivery Room Stabilization
The initial stabilization of the preterm infant in the delivery room sets the stage for subsequent respiratory management. Delayed cord clamping for 60 seconds or longer is recommended when the clinical condition allows, as this improves cardiovascular stability and reduces the need for transfusion. If stabilization with intact cord can be safely undertaken, longer deferred cord clamping is preferable, especially in infants under 34 weeks' gestation. If deferred cord clamping is not feasible, umbilical cord milking may be considered in infants at 28 weeks' gestation or more.
Non-invasive respiratory support should be initiated from birth in all infants at risk of RDS who do not require intubation for stabilization. Nasal continuous positive airway pressure at 6 to 8 cm H2O or, if available, synchronized nasal intermittent positive pressure ventilation should be used as the primary mode of support. The use of T-piece devices is recommended rather than self-inflating or flow-inflating bags for mask ventilation. Oxygen for resuscitation should be controlled using a blender, with starting FiO2 of 0.6 for infants under 29 weeks' gestation, at least 0.30 for infants 29 to 31 weeks, and 0.21 for infants 32 weeks' gestation and above. Intubation should be reserved for infants not responding to positive pressure ventilation via face mask or nasal prongs.
Surfactant Administration
Surfactant replacement therapy remains the cornerstone of RDS management, rapidly improving lung compliance and gas exchange. The 2025 European Consensus Guidelines recommend that surfactant be given early in the course of the disease, while the infant is on non-invasive respiratory support. For infants over 28 weeks' gestation, surfactant should be given to those with worsening RDS, with a suggested protocol administering surfactant to infants on non-invasive support with a mean airway pressure of 6 cm H2O and FiO2 of 0.3 or greater, or where lung ultrasound suggests surfactant need.
The route of surfactant administration has evolved significantly, with thin-catheter administration (also known as Less Invasive Surfactant Administration or LISA, or Minimally Invasive Surfactant Therapy or MIST) now recommended as the preferred technique for spontaneously breathing preterm infants. This technique involves the insertion of a thin catheter through the vocal cords under direct laryngoscopic visualization, allowing surfactant administration while the infant continues to breathe spontaneously on non-invasive support. Compared with traditional intubation-surfactant-extubation (InSurE) techniques, thin-catheter administration reduces the need for mechanical ventilation and may reduce the risk of bronchopulmonary dysplasia.
An initial dose of 200 mg/kg of poractant alfa is recommended, as this higher dose is superior to 100 mg/kg in improving outcomes. A second and occasionally a third dose should be given if there is ongoing evidence of RDS, such as persistent high oxygen requirement, provided other problems have been excluded. Surfactant can be used for RDS complicated by congenital pneumonia and can improve oxygenation following pulmonary hemorrhage.
Non-Invasive Respiratory Support
Non-invasive respiratory support represents the preferred approach for infants with RDS, avoiding the complications associated with endotracheal intubation and mechanical ventilation. Nasal continuous positive airway pressure at 6 to 8 cm H2O is the most widely used mode, providing a constant distending pressure that maintains functional residual capacity and prevents alveolar collapse. Synchronized nasal intermittent positive pressure ventilation, which adds periodic inflating pressures to the continuous distending pressure, may offer advantages over CPAP alone, including reduced work of breathing and improved gas exchange, though the evidence for superiority in preventing bronchopulmonary dysplasia is less clear.
High-flow nasal cannulae, which deliver heated humidified gas at flows exceeding 2 liters per minute, have gained popularity due to their ease of use and perceived comfort. However, evidence suggests that high-flow nasal cannulae may be inferior to CPAP for preterm infants with RDS, and their use as initial therapy is not recommended. They may have a role in weaning from non-invasive support or in infants with mild disease.
The ability to escalate from CPAP to NIPPV may reduce the need for invasive mechanical ventilation in some infants. When weaning from non-invasive support, a gradual reduction in pressure or flow is typically employed, with careful monitoring for signs of respiratory deterioration.
Mechanical Ventilation
When mechanical ventilation is required, lung-protective strategies should be employed to minimize secondary lung injury. Volume-targeted ventilation, in which the ventilator delivers a preset tidal volume regardless of changes in lung compliance, is recommended as the first choice when infants with RDS require mechanical ventilation. This approach reduces the risk of volutrauma compared with pressure-limited ventilation. The initial tidal volume is typically set at 4 to 6 mL/kg, adjusted based on blood gas analysis and clinical assessment.
Permissive hypercapbia is accepted as a lung-protective strategy, with a modest degree of hypercarbia tolerated provided the pH remains above 7.22. Avoidance of hypocapnia is important, as this may increase the risk of brain injury. Positive end-expiratory pressure should be maintained at adequate levels to prevent alveolar collapse, typically 5 to 6 cm H2O. The duration of mechanical ventilation should be minimized, with efforts directed toward early extubation to non-invasive support.
Adjunctive Therapies
Caffeine citrate, administered as a loading dose of 20 mg/kg followed by maintenance dosing of 5 to 10 mg/kg daily, should be used to facilitate weaning from mechanical ventilation and prevent apnea of prematurity. Early caffeine administration in standard doses is recommended for infants under 32 weeks' gestation. Caffeine reduces the frequency of apnea, facilitates extubation, and may reduce the risk of bronchopulmonary dysplasia.
For infants at high risk of death or bronchopulmonary dysplasia who remain on mechanical ventilation after one to two weeks, a short tapering course of low-dose dexamethasone may be considered to facilitate extubation. However, the potential benefits must be weighed against the risks of neurodevelopmental impairment associated with corticosteroid exposure.
Supportive Care
Comprehensive supportive care is essential for infants with RDS. Temperature control should maintain core temperature between 36.5°C and 37.5°C, avoiding both hypothermia and hyperthermia. Fluid management should be individualized, with most infants started on intravenous fluids of 70 to 80 mL/kg/day in a humidified incubator, adjusted based on serum sodium levels, urine output, and weight loss. Parenteral nutrition should be started from birth, with amino acids and lipids introduced early and advanced as tolerated. Enteral feeding with mother's milk should begin as soon as the infant is hemodynamically stable.
Antibiotics should be used judiciously and stopped early when sepsis is ruled out, as the clinical presentation of RDS can be difficult to distinguish from early-onset sepsis. Treatment of hypotension is recommended when there is evidence of poor tissue perfusion. The management of patent ductus arteriosus remains controversial, with pharmacologic closure considered for hemodynamically significant lesions using indomethacin, ibuprofen, or paracetamol.
Long-term Outcomes and Complications
Despite advances in management, respiratory distress syndrome is associated with significant long-term complications. Bronchopulmonary dysplasia, defined as the need for supplemental oxygen at 36 weeks' postmenstrual age, develops in a substantial proportion of very preterm infants with RDS. BPD is associated with prolonged hospitalization, increased risk of respiratory infections, and long-term pulmonary sequelae including asthma and pulmonary hypertension.
Neurodevelopmental impairment represents another major concern, with preterm infants with RDS at increased risk of cerebral palsy, cognitive impairment, and behavioral problems. The risk correlates with the severity of neonatal illness, the presence of complications such as intraventricular hemorrhage and periventricular leukomalacia, and environmental factors including socioeconomic status and access to early intervention services.
Retinopathy of prematurity, necrotizing enterocolitis, and other complications of prematurity may coexist with RDS, compounding the burden of illness. The comprehensive care of infants with RDS extends beyond the neonatal period to include long-term follow-up for pulmonary, neurological, and developmental sequelae.
Discussion
The management of respiratory distress syndrome has undergone remarkable transformation, with contemporary approaches emphasizing non-invasive strategies, lung-protective ventilation, and individualized care. The 2025 European Consensus Guidelines reflect this evolution, recommending thin-catheter surfactant administration as the preferred technique for spontaneously breathing infants, conditional recommendations for non-invasive support modes, and emphasis on avoiding mechanical ventilation when possible.
The shift toward non-invasive respiratory support represents a paradigm change with important implications for outcomes. By avoiding endotracheal intubation and mechanical ventilation, non-invasive strategies reduce the risk of ventilator-associated complications including bronchopulmonary dysplasia, nosocomial infection, and airway trauma. The evidence supporting CPAP as initial therapy is robust, with multiple randomized trials demonstrating reduced need for mechanical ventilation and possibly reduced bronchopulmonary dysplasia compared with early surfactant administration and ventilation.
The evolution of surfactant administration techniques reflects the broader trend toward minimally invasive interventions. Thin-catheter administration (LISA/MIST) offers the advantage of surfactant delivery without the need for intubation and mechanical ventilation, preserving spontaneous breathing and reducing procedural stress. The evidence supporting this technique has grown substantially, with meta-analyses demonstrating reduced need for mechanical ventilation and possibly reduced bronchopulmonary dysplasia compared with traditional InSurE techniques. However, the technique requires appropriate training and expertise, and may not be feasible in all settings.
The optimal management of moderate and late preterm infants with RDS remains an area of uncertainty. These infants, born at 32 to 36 weeks' gestation, represent a substantial proportion of cases and may have atypical presentations that complicate diagnosis and management. The Delphi consensus on management of RDS in moderate and late preterm neonates highlights the lack of evidence specific to this population and the need for further research to guide clinical practice.
The role of lung ultrasound in the diagnosis and management of RDS continues to expand. This radiation-free, bedside technique offers advantages over chest radiography and may guide surfactant administration decisions, monitor treatment response, and differentiate RDS from other causes of respiratory distress. However, standardization of technique and interpretation remains necessary for widespread adoption.
The prevention of bronchopulmonary dysplasia remains a major challenge, with no single intervention proven to eliminate this complication. The combination of antenatal corticosteroids, non-invasive respiratory support, surfactant administration, caffeine therapy, and avoidance of excessive oxygen exposure has reduced the incidence of BPD, but it persists as a significant problem, particularly in the most immature infants. Novel approaches including stem cell therapy, growth factors, and anti-inflammatory agents are under investigation but remain experimental.
Conclusion
Respiratory distress syndrome remains a significant challenge in neonatal care, though remarkable progress has been achieved in reducing mortality and improving outcomes. Contemporary management emphasizes non-invasive respiratory support, early surfactant administration using minimally invasive techniques, and lung-protective strategies that minimize secondary injury. The 2025 European Consensus Guidelines provide a comprehensive framework for management, integrating the latest evidence with expert consensus. Continued research is needed to address persistent challenges including the prevention of bronchopulmonary dysplasia, optimization of management for moderate and late preterm infants, and improvement of long-term neurodevelopmental outcomes. The integration of lung ultrasound, refinement of surfactant administration techniques, and development of novel therapeutic approaches offer promise for further advancing the care of infants with respiratory distress syndrome.
References
Sweet DG, Carnielli VP, Greisen G, et al. European consensus guidelines on the management of respiratory distress syndrome: 2025 update. Neonatology. 2026;123(1):3-23.
Sweet DG, Carnielli VP, Greisen G, et al. European consensus guidelines on the management of respiratory distress syndrome: 2022 update. Neonatology. 2023;120(1):3-23.
Ho JJ, Subramaniam P, Davis PG. Continuous positive airway pressure (CPAP) for respiratory distress in preterm infants. Cochrane Database Syst Rev. 2020;10(10):CD002271.
Fischer HS, Bührer C. Avoiding endotracheal ventilation to prevent bronchopulmonary dysplasia: a meta-analysis. Pediatrics. 2013;132(5):e1351-e1360.
Schmölzer GM, Kumar M, Pichler G, Aziz K, O'Reilly M, Cheung PY. Non-invasive versus invasive respiratory support in preterm infants at birth: systematic review and meta-analysis. BMJ. 2013;347:f5980.
Göpel W, Kribs A, Ziegler A, et al. Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV): an open-label, randomised, controlled trial. Lancet. 2011;378(9803):1627-1634.
Kanmaz HG, Erdeve O, Canpolat FE, Mutlu B, Dilmen U. Surfactant administration via thin catheter during spontaneous breathing: randomized controlled trial. Pediatrics. 2013;131(2):e502-e509.
Dargaville PA, Aiyappan A, De Paoli AG, et al. Minimally-invasive surfactant therapy in preterm infants on continuous positive airway pressure. Arch Dis Child Fetal Neonatal Ed. 2013;98(2):F122-F126.
Isayama T, Iwami H, McDonald S, Beyene J. Association of noninvasive ventilation strategies with mortality and bronchopulmonary dysplasia among preterm infants: a systematic review and meta-analysis. JAMA Pediatr. 2016;170(2):165-174.
Lemyre B, Davis PG, De Paoli AG, Kirpalani H. Nasal intermittent positive pressure ventilation (NIPPV) versus nasal continuous positive airway pressure (NCPAP) for preterm neonates after extubation. Cochrane Database Syst Rev. 2017;2(2):CD000212.
Wilkinson D, Andersen C, O'Donnell CP, De Paoli AG, Manley BJ. High flow nasal cannula for respiratory support in preterm infants. Cochrane Database Syst Rev. 2016;2(2):CD006405.
Rojas-Reyes MX, Morley CJ, Soll R. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2012;3(3):CD000510.
Soll RF, Blanco F. Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Cochrane Database Syst Rev. 2001;(2):CD000144.
Pfister RH, Soll RF, Wiswell T. Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome. Cochrane Database Syst Rev. 2009;(4):CD006180.